1. bookVolume 29 (2021): Issue 3 (July 2021)
Journal Details
License
Format
Journal
First Published
08 Aug 2013
Publication timeframe
4 times per year
Languages
English
access type Open Access

Correction factor between two calcitonin assays: DiaSorin LiaisonXL and Cobas E601

Published Online: 31 Jul 2021
Page range: 271 - 276
Received: 13 Jun 2021
Accepted: 13 Jul 2021
Journal Details
License
Format
Journal
First Published
08 Aug 2013
Publication timeframe
4 times per year
Languages
English
Abstract

Introduction: Calcitonin measurement is important for the diagnosis and monitoring of medullary thyroid carcinoma. Unfortunately, in clinical practice, different detection systems assays are used in the follow-up of the patients, which can be misleading.

Objective: To identify the correction factor for calcitonin measurement on two different immunoanalysers: DiaSorin-LiaisonXL (immunochemiluminescence) and CobasE601 (electro-immunochemiluminescence).

Methods: We selected 89 registered CT samples (28-from men; 61-from women), that were analysed on CobasE601 with reported values between 0.5 pg/ml and 2812 pg/ml (128.5±513.98). These CT samples were selected randomly to cover as wide a range of values as possible, and represented either basal CT (n=38) or selected from CT stimulation tests (n=51). Samples were evaluated subsequently on DiaSorin-LiaisonXL. All patients gave their informed consent.

Results: Between the two assays a segmented linear correlation was noted. We identified the following general linear regression equation: 1.108x+19.337 (p<0.05). The bias increased at high calcitonin values. Therefore, for a better accuracy we analysed the regression equation segmentally. A statistic difference (p<0.05) was noted for CT values ranged between 350-2600 pg/ml (n=31) on DiaSorin-LiaisonXL, for which the linear regression equation for CobasE601 becomes 1.009x+169.796.

Conclusions: Calcitonin correction factors are highly important in the dynamic follow up of a patient suffering from medullary thyroid carcinoma when different detection systems assays are used to determine calcitonin. We identified the correction factors for calcitonin determination between two different frequently used chemiluminescence immunoanalysers: DiaSorin-LiaisonXL and CobasE601. However, it is strongly advisable to use the same analyser in order to establish biochemical evolution of calcitonin.

Keywords

1. Gardner DG, Shoback MD. Metabolic bone disease. In: Greenspan’s Basic & Clinical Endocrinology, Tenth Edition. Ohio: McGraw-Hill; 2018. p. 239-297. Search in Google Scholar

2. Castagna MG, Fugazzola L, Maino F, Covelli D, Memmo S, Sestini F, et al. Reference range of serum calcitonin in pediatric population. J Clin Endocrinol Metab. 2015 May;100(5):1780-4. DOI: 10.1210/jc.2014-4508 Search in Google Scholar

3. Wells SA, Asa SL, Dralle H, Elisei R, Evans DB, Gagel RF, et al. Revised American thyroid association guidelines for the management of medullary thyroid carcinoma. Thyroid. 2015 Jun;25(6):567-610. DOI: 10.1089/thy.2014.0335 Search in Google Scholar

4. Eckelt F, Vogel M, Geserick M, Kirsten T, Bae YJ, Baber R, et al. Calcitonin measurement in pediatrics: Reference ranges are gender-dependent, validation in medullary thyroid cancer and effects of thyroid diseases. Clin Chem Lab Med. 2019 Jun;57(8):1242-50. DOI: 10.1515/cclm-2018-1186 Search in Google Scholar

5. Danila R, Livadariu R, Branisteanu D. Calcitonin revisited in 2020. Acta Endocrinol (Buchar) 2019 Oct-Dec;15(4):544-8. DOI: 10.4183/aeb.2019.544 Search in Google Scholar

6. Băetu M, Dobrescu R. Novel markers for early diagnosis and prognostic classification in medullary thyroid carcinoma. Acta Endocrinol (Buchar). 2017 Oct;13(4):519-522. DOI: 10.4183/aeb.2017.519 Search in Google Scholar

7. Hillyard CJ, Oscier DG, Foa R, Catovsky D, Goldman JM. Immunoreactive calcitonin in leukaemia. Br Med J. 1979 Dec;2(6202):1392-3. DOI: 10.1136/bmj.2.6202.1392 Search in Google Scholar

8. Schwartz KE, Wolfsen AR, Forster B, Odell WD. Calcitonin in nonthyroidal cancer. J Clin Endocrinol Metab. 1979 Sep;49(3):438-44. DOI: 10.1210/jcem-49-3-438 Search in Google Scholar

9. Toledo SPA, Lourenço DM, Santos MA, Tavares MR, Toledo RA, Correia-DeurI JE de M. Hypercalcitoninemia is not pathognomonic of medullary thyroid carcinoma. Clinics. 2009 Jul;64(7):699-706. DOI: 10.1590/S1807-59322009000700015 Search in Google Scholar

10. Barbet J, Campion L, Kraeber-Bodéré F, et al. Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma. J Clin Endocrinol Metab 2005 Nov;90(11):6077-6084. DOI: 10.1210/jc.2005-0044 Search in Google Scholar

11. Ito Y, Miyauchi A, Kihara M, et al. Calcitonin doubling time in medullary thyroid carcinoma after the detection of distant metastases keenly predicts patients’ carcinoma death. Endocr J 2016 Jul;63(7):663-7. DOI: 10.1507/endocrj.EJ16-0140 Search in Google Scholar

12. LIAISON® XL | DiaSorin. Available from: https://www.diasorin.com/en/immunodiagnostic-solutions/systems/clia-systems/liaisonr-xl. Accessed Mar 19, 2021. Search in Google Scholar

13. Elecsys® Calcitonin. Available from: https://diagnostics.roche.com/global/en/products/params/elecsys-calcitonin.html. Accessed Mar 19, 2021. Search in Google Scholar

14. Kahaly GJ, Algeciras-Schimnich A, Davis TE, Diana T, Feldkamp J, Karger S, et al. United States and european multicenter prospective study for the analytical performance and clinical validation of a novel sensitive fully automated immunoassay for calcitonin. Clin Chem. 2017 Sep;63(9):1489-96. DOI: 10.1373/clinchem.2016.270009 Search in Google Scholar

15. Kratzsch J, Petzold A, Raue F, Reinhardt W, Bröcker-Preuß M, Görges R, et al. Basal and stimulated calcitonin and procalcitonin by various assays in patients with and without medullary thyroid cancer. Clin Chem. 2011 Mar;57(3):467-74. DOI: 10.1373/clinchem.2010.151688 Search in Google Scholar

16. Shi J, Shi Q, Yuan S, Zhang W. Relationships between serum procalcitonin level, severity and different stresses of non-septic critically ill patients. Rev Romana Med Lab. 2020;28(1):49-56. DOI:10.2478/rrlm-2020-0003 Search in Google Scholar

17. Vashist SK, Luong JHT. Handbook of Immunoassay Technologies: Approaches, Performances, and Applications. London: Academic Press; 2018. DOI: 10.1016/B978-0-12-811762-0.05001-5 Search in Google Scholar

18. Ross DS. Medullary thyroid cancer: Surgical treatment and prognosis - UpToDate Available from: https://www.uptodate.com/contents/diagnostic-approach-to-and-treatment-of-thyroid-nodules. Accessed Mar 19, 2021. Search in Google Scholar

Recommended articles from Trend MD

Plan your remote conference with Sciendo